Photodynamic therapy for bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a light-activated drug called cosiporfin sodium for people with advanced bile duct cancer that cannot be surgically removed. The treatment targets tumors in the bile ducts and may help shrink them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of bile duct cancer that has spread or come back and cannot be surgically removed.
- You have not received any chemotherapy or other systemic therapy for advanced disease.
- You have tumors outside the bile ducts that can be measured on scans.
- You are able to perform daily activities with little or no help (ECOG 0-1).
- Your major organs (bone marrow, kidneys, liver, heart) are working well enough based on blood tests and heart tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of treatments—a wearable device that sends electric fields to the tumor area (tumor-treating fields) plus immunotherapy (durvalumab) and chemotherapy (gemcitabine/cisplatin)—for people with advanced bile duct or gallbladder cancer. It may be an option if you haven't had chemotherapy for advanced disease before.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests a combination of two immunotherapy drugs with chemotherapy for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (PD-1/PD-L1 inhibitor) as the first treatment for advanced bile duct or gallbladder cancer. It aims to see if this combination works better and to understand how the immune system responds.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
Hear when a new Biliary Tract Cancers (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.